|
π¦
|
A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.
K. Ramadan,
T. Shenkier,
L. Sehn,
R. Gascoyne,
J. Connors
|
7 |
2006 |
7
π¦
|
|
π
|
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
24 auth.
D. Villa,
M. Crump,
T. Panzarella,
K. Savage,
C. Toze,
D. Stewart,
D. Macdonald,
R. Buckstein,
Christina R. Lee,
Mohsen Alzahrani,
...
M. Rubinger,
R. Foley,
A. Xenocostas,
M. Sabloff,
A. Muccilli,
N. Chua,
F. Couture,
J. Larouche,
S. Cohen,
J. Connors,
Kimberley L. S. Ambler,
A. Al-Tourah,
K. Ramadan,
J. Kuruvilla
|
6 |
2013 |
6
π
|
|
π
|
Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy
10 auth.
H. Leitch,
C. LeΜger,
Trisha A. Goodman,
K. Wong,
Dominica H. C. Wong,
K. Ramadan,
...
M. Rollins,
M. Barnett,
P. Galbraith,
L. Vickars
|
6 |
2008 |
6
π
|
|
π¬
|
Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
H. Leitch,
Christopher Chan,
C. LeΜger,
L. Foltz,
K. Ramadan,
L. Vickars
|
5 |
2012 |
5
π¬
|
|
π
|
Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008
10 auth.
V. Mak,
D. Ip,
O. Mang,
Chinmay B. Dalal,
Steven J. Huang,
A. Gerrie,
...
T. Gillan,
K. Ramadan,
C. Toze,
W. Au
|
5 |
2014 |
5
π
|
|
π
|
Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy
12 auth.
H. Leitch,
Jocelyn M. Chase,
Trisha A. Goodman,
Hatoon M. Ezzat,
M. Rollins,
Dominic H.C. Wong,
...
M. Badawi,
C. LeΜger,
K. Ramadan,
M. Barnett,
L. Foltz,
L. Vickars
|
5 |
2009 |
5
π
|
|
π
|
Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials
7 auth.
A. Gerrie,
C. Toze,
K. Ramadan,
Charles H. Li,
J. Sutherland,
Adrian Yee,
...
J. Connors
|
4 |
2012 |
4
π
|
|
π¦
|
Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results
19 auth.
K. Ramadan,
J. Connors,
A. Al-Tourah,
K. Song,
R. Gascoyne,
M. Barnett,
T. Nevill,
J. Shepherd,
S. Nantel,
H. Sutherland,
...
D. Forrest,
D. Hogge,
J. C. Lavoie,
Y. Abou-Mourad,
M. Chhanabhai,
N. Voss,
R. Brinkman,
C. Smith,
C. Toze
|
4 |
2008 |
4
π¦
|
|
π
|
Excellent realβworld outcomes of adults with Burkitt lymphoma treated with CODOXβM/IVAC plus or minus rituximab
21 auth.
K. Zhu,
K. Song,
J. Connors,
H. Leitch,
M. Barnett,
K. Ramadan,
G. Slack,
Y. A. Abou Mourad,
D. Forrest,
D. Hogge,
...
S. Nantel,
S. Narayanan,
T. Nevill,
M. Power,
D. Sanford,
H. Sutherland,
T. Tucker,
C. Toze,
L. Sehn,
R. Broady,
A. Gerrie
|
4 |
2018 |
4
π
|
